Full-Time
Mass Spectrometry Sales Manager
Posted on 3/3/2026
Thermo Fisher Scientific
10,001+ employees
Supplies laboratory instruments, reagents, diagnostics
No salary listed
Melbourne VIC, Australia + 1 more
More locations: Sydney NSW, Australia
In Person
Must be willing to travel to customer locations.
 Sales & Account Management (2) |
|---|
| , |
- Bachelor's degree in a scientific discipline
- 5 years of Complex instrumentation solutions sales experience
- 5 years in people management role
- Able and willing to travel to customer locations
- Ability to comfortably operate across a global and matrix organization
- Lead the strategic direction for the overall ANZ region for the portfolio; leading a sales team to drive strategies to meet plan and expand business
- Drive commercial effectiveness across the team, ensuring they build and maintain a pipeline of opportunities to meet or exceed sales objectives
- Focus the organisation on satisfying customers and delivering on the wider Thermo Fisher value proposition. Establish relationships with key customers across the region with regular sales calls and a strategic partnership approach
- Research competitor and industry activity and keep informed of new products/services and other general information of interest to customers incorporating this data in the business plan; Introduce new products and services
- Build product and marketing strategy in partnership with global and regional strategy to drive strong business performance that capitalises on market opportunity
- Show initiative to develop programs to drive growth in any economic condition
- Maintain accurate reporting, records, and files vital for proper management of region
- Build, develop and mentor an impactful team, creating a successful work environment, implementing performance standards, development and training plans and planning for succession
- Positively represent Thermo Fisher Scientific at all times throughout customer locations
- Develop a keen understanding of our local industry business and service needs, and partner with Division guides regionally and globally to meet local needs
- As a member of the CMD management team, contribute to the overall business success and partner seamlessly across commercial and service to drive revenue growth and customer allegiance
- LSMS & HPLC experience (preferred)
- Experience leading a team of technical sales specialists (preferred)
- Advanced selling and presentation skills (preferred)
Thermo Fisher Scientific provides life sciences tools and services for research, healthcare, and industry. Its products include laboratory instruments, reagents, consumables, and software for activities like protein biology, PCR, sequencing, and bioprocessing. It differentiates itself with an end-to-end footprint across trusted brands and strong customer support and education, plus direct sales and promotions. Its goal is to help make the world healthier, cleaner, and safer by enabling discovery, diagnostics, and quality manufacturing across research institutions, healthcare providers, and government bodies.
Company Size
10,001+
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
1956
Simplify's Take
What believers are saying
- Clario $9B acquisition completed Q1 2026 drives clinical trial data synergies through 2028.
- Q1 2026 bioproduction strength raises FY revenue guidance to $47.3–48.1 billion.
- Reshoring tailwinds boost biomanufacturing from 2027 per management outlook.
What critics are saying
- Academic and government markets contract in US and China through 2027, slashing consumables sales.
- Microbiology sale to Astorg closes H2 2026, diluting EPS $0.15 with $645M revenue loss.
- Tariffs and inflation erode 80 basis points of margins amid US-China tensions.
What makes Thermo Fisher Scientific unique
- Thermo Fisher integrates instruments, reagents, and services across Thermo Scientific, Applied Biosystems, and Invitrogen brands.
- Gibco CTS DynaXS bioreactor launched May 4, 2026, enables scalable cell therapy from research to cGMP.
- Plainville Bioprocess Design Center opened April 28, 2026, offers end-to-end bioproduction workflow collaboration.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Fertility Treatment Support
Family Planning Benefits
Professional Development Budget
Conference Attendance Budget
Wellness Program
Mental Health Support
Gym Membership
Phone/Internet Stipend
Home Office Stipend
Company News
Thermo Fisher Scientific unveils an integrated platform to advance scalable Cell Therapy manufacturing. Published at May 4th 2026, 8:30 AM EDT via Business Wire i This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. New Gibco(TM) CTS(TM) DynaXS(TM) Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical production to support the development of cell therapies for cancer, autoimmune, and other treatments Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco(TM) CTS(TM) DynaXS(TM) Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to scalable, automation-ready platforms that can support consistent quality, cost control, and cGMP compliance. Developers must balance process flexibility with the operational demands of clinical manufacturing, often within limited facility space and tight development timelines. At the same time, the cell therapy landscape continues to evolve beyond oncology into a broader range of indications, including autoimmune and other emerging areas. This shift is driving the development of new cell modalities and diverse manufacturing approaches. These emerging applications often require different process configurations and production scales, adding complexity to manufacturing strategies across all stages of development and commercialization. The CTS DynaXS Single Use Bioreactor was designed specifically to address these evolving needs. The stirred-tank, single-use system supports cell expansion across development and early clinical volumes, offering a scalable platform from small process development batches to larger cGMP manufacturing runs. "Cell therapy manufacturers are navigating a rapidly expanding pipeline and increasing regulatory expectations," said Sara Henneman, vice president and general manager of Thermo Fisher Scientific's cell culture and cell therapy business. "The CTS DynaXS bioreactor reflects our commitment to help deliver end-to-end, integrated solutions that enable customers to simplify scale-up, strengthen process control, and support the development of therapies intended for patient use." Integrated Within the CTS Cell Therapy Ecosystem The CTS DynaXS bioreactor extends Thermo Fisher's Cell Therapy Systems (CTS) portfolio, supporting workflows from cell isolation and activation through expansion and downstream processing. This integration enables customers to build modular, scalable manufacturing strategies with unified technical support and regulatory documentation. "Manufacturers want platforms that grow with them," said Andy Campbell, senior director of research and development at Thermo Fisher Scientific. "With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types." Thermo Fisher's Commitment to Cell Therapy Innovation Spans Over 20 Years As demand for scalable, reproducible cell therapy manufacturing solutions accelerates, Thermo Fisher remains committed to supporting customers with technologies designed to reduce complexity, enhance control, and support progress toward clinical development. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of more than $45 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com. Contacts. Report this content If you believe this article contains misleading, harmful, or spam content, please let us know.
Thermo Fisher Scientific has announced multiple collaborations strengthening its precision health capabilities, including a data partnership with HealthVerity providing access to claims data on over 270 million de-identified US patients across 70 linked sources. The company has also launched proteomics initiatives and new cell therapy tools. The HealthVerity collaboration enhances Thermo Fisher's PPD unit's real-world evidence and trial optimisation services, supporting its ambition to serve as an end-to-end partner in clinical development. The moves deepen the company's integration of large-scale data, high-throughput proteomics and automated manufacturing across the biopharma value chain. The company's narrative projects $50 billion revenue and $9 billion earnings by 2028, requiring 5% annual revenue growth. However, investors face risks from potential margin pressure due to tariffs and policy uncertainty.
Thermo Fisher Scientific's PPD clinical research business forms data-focused collaboration. April 13, 2026- Thermo Fisher Scientific announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher's PPD(TM) clinical research business will gain enterprise-level access to HealthVerity's TaXOnomy(R) claims dataset, representing more than 270 million de-identified patient lives across the U.S. healthcare system. The datasets will provide deep insights into disease prevalence, treatment patterns and provider activity, further strengthening the clinical research business' data and AI driven services across trial feasibility and optimization, recruitment and real-world evidence generation. The agreement also provides access to a marketplace of more than 70 curated data sources, including electronic medical records, laboratory results and other specialty datasets. With streamlined access to longitudinal claims and linked datasets, the business can deliver more precise site selection strategies and improved startup timelines.
Thermo Fisher Scientific has partnered with Singapore's PRECISE to support the PRECISE SG100K biobank initiative. The company will supply integrated multi-platform proteomics capabilities, including Olink PEA and Orbitrap Astral mass spectrometry, alongside partners Seer and Novogene. The collaboration aims to support population-scale precision medicine research and biomarker discovery across the Asia Pacific region. The stock currently trades at $496.11, approximately 32.7% below the analyst target of $658.40. Thermo Fisher's Life Sciences segment generates $44.6 billion in revenue, with a P/E ratio of 27.5x compared to the industry average of 37.3x. However, analysts note earnings have declined 5% annually over five years, and debt coverage by operating cash flow remains a concern.
NovogeneAIT Genomics appointed as service provider to advance large-scale proteomics for PRECISE-SG100K cohort in Singapore. 2026-04-10 12:44 551 SINGAPORE, April 10, 2026 /PRNewswire/ - NovogeneAIT Genomics announces its appointment as the designated service provider for the PRECISE-SG100K proteomics project. In this role, NovogeneAIT Genomics will process and generate data from 10,000 plasma samples from the PRECISE-SG100K cohort led by Thermo Fisher Scientific in collaboration with PRECISE to support precision medicine research in Singapore. This landmark project will utilize Thermo Fisher Scientific's Orbitrap Astral mass spectrometry platform, coupled with Seer's Proteograph Product Suite and Olink's Reveal Assay. Together, these advanced technologies will enable deep proteomic profiling of 10,000 samples. This study aims to demonstrate the profound value of deep, unbiased plasma proteomics, enabling high-throughput analysis and the discovery of novel biomarkers and biological signatures associated with aging and disease. "Being appointed as the service lab for this landmark study represents a major leap forward in our capability to support large-scale proteomics research in Singapore," said John Zhang, Senior Commercial director of NovogeneAIT. Together, with Thermo Fisher Scientific and Seer, Polkadot PR Pty Ltd is uniquely positioned to deliver deep, actionable insights from this cohort and contribute meaningfully to Singapore's National Precision Medicine Program." Prof. John Chambers, Chief Scientific Officer at PRECISE and lead Principal Investigator of the PRECISE-SG100K cohort, highlighted the importance of this partnership: "This collaboration further strengthens the PRECISE-SG100K dataset, through addition of mass spectroscopy based assessment of proteomic variation. The results will enable our researchers to carry out integrated analyses across different layers of biology. Such efforts are important for improving our understanding of disease mechanisms and supporting future translational research." The successful completion of this 10,000 sample pilot study is expected to serve as a robust proof of concept. It will demonstrate the immense value of complementary proteomics and support the broader expansion of a multi-omics approach for the PRECISE-SG100K cohort. About NovogeneAIT Genomics NovogeneAIT Genomics is a leading multi-omics services and solutions provider headquartered in Singapore. Established as a joint venture between Novogene and AITbiotech, it has grown to become one of the largest multi-omics service providers in Southeast Asia. The company offers a comprehensive suite of services, including genomics, transcriptomics, single cell and spatial transcriptomics, metagenomics and proteomics. NovogeneAIT Genomics delivers high-quality omics solutions to support research across various sectors, including healthcare and agriculture. About PRECISE-SG100K The PRECISE-SG100K study is a landmark long-term research project that has successfully completed its recruitment phase, having engaged over 100,000 participants from Singapore's diverse, multi-ethnic population. This comprehensive study has collected extensive baseline health information and biological specimens from participants across the nation. Moving forward, the study will continue to monitor long-term health outcomes and identify environmental, lifestyle and genetic factors associated with diseases such as diabetes, hypertension, and cancer. As one of the largest population health studies in Southeast Asia, PRECISE-SG100K represents a significant milestone for health research in Singapore and is positioned to yield globally significant results that will advance precision medicine and improve health outcomes for diverse populations worldwide. For more information, please visit Phase II: PRECISE SG100K.